Although there is clear and mounting evidence for the role of IL-6 and IL-11-mediated STAT3 signaling in tumor establishment, proliferation, immune evasion and metastatic disease, to date there are no FDA-approved therapies which target the IL-6/IL-11/STAT3 axis for use in the treatment of any breast cancer subtype. This evidence concerns the gene IL11 and neoplasm.